派林生物(000403) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥374,649,641.98, a decrease of 14.00% compared to ¥435,640,719.29 in the same period last year[6] - Net profit attributable to shareholders was ¥89,089,215.65, down 26.95% from ¥121,948,626.85 year-on-year[6] - Basic earnings per share decreased by 29.41% to ¥0.12 from ¥0.17 in the same period last year[6] - Net profit for the period was ¥88,939,547.68, down from ¥121,869,775.56, representing a decline of approximately 27%[22] - Total operating revenue decreased to ¥374,649,641.98 from ¥435,640,719.29, a decline of approximately 14%[21] - Total operating costs reduced to ¥276,480,817.30 from ¥297,485,500.88, reflecting a decrease of about 7%[21] Cash Flow - The net cash flow from operating activities was -¥115,839,348.29, representing a decline of 123.36% compared to -¥51,862,351.40 in the previous year[6] - Total cash inflow from operating activities was 504,109,212.86 CNY, down 10.67% from 564,474,916.40 CNY in the previous period[25] - Cash outflow from operating activities totaled 619,948,561.15 CNY, slightly increased from 616,337,267.80 CNY in the previous period[25] - Cash flow from investment activities showed a net outflow of -546,717,554.17 CNY, worsening from -440,371,925.58 CNY in the previous period[25] - The net cash flow from financing activities was 8,119,220.71 CNY, a decline from 51,599,071.36 CNY in the previous period[25] - The ending cash and cash equivalents balance was 665,919,948.78 CNY, down from 987,647,622.30 CNY in the previous period[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥9,196,700,838.85, a decrease of 0.54% from ¥9,246,269,365.26 at the end of the previous year[6] - Total current assets at the end of the reporting period amount to 3,469,649,834.08 yuan, a decrease from 3,578,948,533.75 yuan at the beginning of the period[17] - Total liabilities decreased to ¥1,190,259,363.13 from ¥1,328,766,729.91, a reduction of about 10%[19] - Non-current assets totaled ¥5,727,051,004.77, up from ¥5,667,320,831.51, an increase of approximately 1%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 29,271[14] - The largest shareholder, Qiongqing City Shengbang Yinghao Investment Partnership, holds 21.03% of shares, totaling 153,752,812 shares, with 123,002,200 shares pledged[14] - The second largest shareholder, Harbin Tongzhi Cheng Technology Development Co., Ltd., holds 10.99% of shares, totaling 80,381,128 shares, with 30,723,000 shares pledged[14] Production and Expansion - The company is expanding production capacity, with Harbin Paisfeico's capacity increasing to 1,600 tons and Guangdong Shuanglin's expected to reach 1,500 tons by mid-2025, totaling over 3,000 tons[6] - The company anticipates improved performance in 2025 due to the completion of capacity expansions, which will support sustainable growth[6] Research and Development - Research and development expenses were ¥10,126,449.49, down 51.47% from ¥20,864,588.50, mainly due to reduced material usage[12] - The company reported an increase in development expenditures to ¥131,852,297.21 from ¥109,769,448.82, an increase of approximately 20%[20] - The company is in the process of obtaining clinical trial approval for new indications through its wholly-owned subsidiary[16] Strategic Initiatives - The company has announced a strategic cooperation agreement, indicating potential market expansion[16] - The company plans to use idle raised funds for temporary liquidity support[16]